- Home
- PUMP vs VTYX Comparison
PUMP vs VTYX Comparison
Compare PUMP & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PUMP | VTYX |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 990.9M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PUMP | VTYX |
|---|---|---|
| Price | $11.18 | $13.95 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 7 |
| Target Price | $12.14 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 3.3M | 3.0M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,300,037,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.51 | $0.78 |
| 52 Week High | $12.14 | $25.00 |
Technical Indicators
Market Signals| Indicator | PUMP | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 73.84 |
| Support Level | $10.36 | $13.89 |
| Resistance Level | $12.14 | $13.98 |
| Average True Range (ATR) | 0.72 | 0.05 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 48.71 | 43.72 |
Price Performance
Historical ComparisonAbout PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.